Santen Pharmaceutical Co

Company Profile

Santen Pharmaceutical Co had its IPO on under the ticker symbol SNPHY.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Santen Pharmaceutical Co has a staff strength of 4,144 employees.

Stock update

Shares of Santen Pharmaceutical Co opened at $9.68 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.52 - $9.68, and closed at $9.52.

This is a +0.63% increase from the previous day's closing price.

A total volume of 3,457 shares were traded at the close of the day’s session.

In the last one week, shares of Santen Pharmaceutical Co have increased by +3.03%.

Santen Pharmaceutical Co's Key Ratios

Santen Pharmaceutical Co has a market cap of $3.53 billion, indicating a price to book ratio of 1.3902 and a price to sales ratio of 0.0114.

In the last 12-months Santen Pharmaceutical Co’s revenue was $285.89 billion with a gross profit of $156.59 billion and an EBITDA of $56.53 billion. The EBITDA ratio measures Santen Pharmaceutical Co's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Santen Pharmaceutical Co’s operating margin was 13.89% while its return on assets stood at 5.66% with a return of equity of -3.5%.

In Q2, Santen Pharmaceutical Co’s quarterly earnings growth was a positive 66.1% while revenue growth was a positive 10.5%.

Santen Pharmaceutical Co’s PE and PEG Ratio

Forward PE

12.9199

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.19 per share while it has a forward price to earnings multiple of 12.9199 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Santen Pharmaceutical Co’s profitability.

Santen Pharmaceutical Co stock is trading at a EV to sales ratio of 0.0098 and a EV to EBITDA ratio of 0.1538. Its price to sales ratio in the trailing 12-months stood at 0.0114.

Santen Pharmaceutical Co stock pays annual dividends of $32 per share, indicating a yield of 2.38% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$416.53 billion

Total Liabilities

$76.19 billion

Operating Cash Flow

$0

Capital Expenditure

$2.94 billion

Dividend Payout Ratio

0%

Santen Pharmaceutical Co ended 2024 with $416.53 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $416.53 billion while shareholder equity stood at $300.93 billion.

Santen Pharmaceutical Co ended 2024 with $0 in deferred long-term liabilities, $76.19 billion in other current liabilities, 8707000000.00 in common stock, $242.66 billion in retained earnings and $0 in goodwill. Its cash balance stood at $45.51 billion and cash and short-term investments were $47.09 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.

Santen Pharmaceutical Co’s total current assets stands at $203.27 billion while long-term investments were $0 and short-term investments were $1.58 billion. Its net receivables were $103.83 billion compared to accounts payable of $41.33 billion and inventory worth $42.23 billion.

In 2024, Santen Pharmaceutical Co's operating cash flow was $0 while its capital expenditure stood at $2.94 billion.

Comparatively, Santen Pharmaceutical Co paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.52

52-Week High

$9.68

52-Week Low

$6.2

Analyst Target Price

$

Santen Pharmaceutical Co stock is currently trading at $9.52 per share. It touched a 52-week high of $9.68 and a 52-week low of $9.68. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $8.89 and 200-day moving average was $8.36 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 1.7% are held by institutions.